Zydus Lifesciences ki Ankleshwar, Gujarat mein Unit-2 manufacturing facility ka USFDA inspection 19 se 23 January 2026 tak chala aur ismein teen observations aayi hain. Company ne turant is par response dete hue kaha ki US regulator ne koi data-integrity se judi observations nahi di hain. Pharmaceutical firm ne stakeholders ko assure kiya ki woh noted observations ko USFDA ke saath milkar promptly resolve karenge. Yeh regulatory update aise samay aayi hai jab Zydus Lifesciences ne pichle hafte India mein Nivolumab ka world's first biosimilar, Tishtha, launch kiya tha. Yeh drug 100 mg aur 40 mg dosages mein available hai, jinki price Rs 28,950 aur Rs 13,950 hai. Pichli trading session mein Zydus Lifesciences ke shares Rs 881.95 par band hue, jo ki 0.33% ki girawat thi. Stock ne pehle 19 September 2025 ko Rs 1,059.00 ka 52-week high aur 07 April 2025 ko Rs 797.05 ka 52-week low touch kiya tha. Currently, stock apne peak se 16.72% neeche aur apne lowest point se 10.65% upar trade kar raha hai. Company ki market capitalization Rs 88,744.81 crore hai.
Zydus Lifesciences ke shares gire USFDA ke Gujarat plant observations ke baad
HEALTHCAREBIOTECH
Overview
Zydus Lifesciences ke shares par nazar hai kyunki Gujarat plant ko USFDA se teen observations mili hain. Inspection 23 January 2026 ko khatam hui. Company ne clear kiya ki koi data integrity issues nahi mile hain, aur woh observations jaldi resolve karenge.
Disclaimer:This content
is for educational and informational purposes only and does not constitute investment, financial, or
trading advice, nor a recommendation to buy or sell any securities. Readers should consult a
SEBI-registered advisor before making investment decisions, as markets involve risk and past performance
does not guarantee future results. The publisher and authors accept no liability for any losses. Some
content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views
expressed do not reflect the publication’s editorial stance.